Intervention with an anti-CSF1/CSF1R antibody was found to normalize the tumor microenvironment, indicating that targeting the CSF1/CSF1R axis might be a potential treatment for malignant meningiomas (99). This evidence concerns the gene CSF1 and neoplasm.